ES2655437T3 - Péptidos de ECT2 y vacunas que incluyen los mismos - Google Patents
Péptidos de ECT2 y vacunas que incluyen los mismos Download PDFInfo
- Publication number
- ES2655437T3 ES2655437T3 ES11762265.4T ES11762265T ES2655437T3 ES 2655437 T3 ES2655437 T3 ES 2655437T3 ES 11762265 T ES11762265 T ES 11762265T ES 2655437 T3 ES2655437 T3 ES 2655437T3
- Authority
- ES
- Spain
- Prior art keywords
- present
- cancer
- peptide
- hla
- peptides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract description 50
- 102000004196 processed proteins & peptides Human genes 0.000 title description 22
- 101000817237 Homo sapiens Protein ECT2 Proteins 0.000 title description 5
- 102100040437 Protein ECT2 Human genes 0.000 title description 5
- 229960005486 vaccine Drugs 0.000 title description 5
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 abstract 1
- 108091005601 modified peptides Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 27
- 108091033319 polynucleotide Proteins 0.000 description 27
- 102000040430 polynucleotide Human genes 0.000 description 27
- 239000002157 polynucleotide Substances 0.000 description 27
- 201000011510 cancer Diseases 0.000 description 23
- 239000000203 mixture Substances 0.000 description 22
- 150000001413 amino acids Chemical class 0.000 description 20
- 239000000126 substance Substances 0.000 description 18
- 235000001014 amino acid Nutrition 0.000 description 17
- 238000000034 method Methods 0.000 description 16
- 239000013598 vector Substances 0.000 description 16
- 239000004480 active ingredient Substances 0.000 description 14
- 230000002265 prevention Effects 0.000 description 14
- 102000011786 HLA-A Antigens Human genes 0.000 description 12
- 108010075704 HLA-A Antigens Proteins 0.000 description 12
- 238000011282 treatment Methods 0.000 description 11
- 238000011321 prophylaxis Methods 0.000 description 10
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 108020004705 Codon Proteins 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 239000008177 pharmaceutical agent Substances 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000010647 peptide synthesis reaction Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 230000002980 postoperative effect Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 101150074651 ECT2 gene Proteins 0.000 description 3
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000005809 anti-tumor immunity Effects 0.000 description 3
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000037452 priming Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 238000011510 Elispot assay Methods 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 2
- 101100395310 Homo sapiens HLA-A gene Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 108010046117 N-palmitoyl-5,6-dipalmitoyl-S-glycerylcysteinyl-seryl-serine Proteins 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 210000001808 exosome Anatomy 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- XVQKZSLOGHBCET-INVHGPFASA-N tripalmitoyl-S-glyceryl-cysteinyl-seryl-serine Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O)CSCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC XVQKZSLOGHBCET-INVHGPFASA-N 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- UHBYWPGGCSDKFX-UHFFFAOYSA-N carboxyglutamic acid Chemical compound OC(=O)C(N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-UHFFFAOYSA-N 0.000 description 1
- -1 cationic lipid Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000011324 primary prophylaxis Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32057710P | 2010-04-02 | 2010-04-02 | |
| US320577P | 2010-04-02 | ||
| PCT/JP2011/001909 WO2011122022A1 (en) | 2010-04-02 | 2011-03-30 | Ect2 peptides and vaccines including the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2655437T3 true ES2655437T3 (es) | 2018-02-20 |
Family
ID=44711777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11762265.4T Active ES2655437T3 (es) | 2010-04-02 | 2011-03-30 | Péptidos de ECT2 y vacunas que incluyen los mismos |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8951975B2 (enExample) |
| EP (1) | EP2553096B1 (enExample) |
| JP (1) | JP5816965B2 (enExample) |
| KR (1) | KR101863557B1 (enExample) |
| CN (1) | CN102939379B (enExample) |
| AR (1) | AR081065A1 (enExample) |
| AU (1) | AU2011233401B2 (enExample) |
| BR (1) | BR112012024997B1 (enExample) |
| CA (1) | CA2795318C (enExample) |
| CO (1) | CO6571869A2 (enExample) |
| DK (1) | DK2553096T3 (enExample) |
| EA (1) | EA027940B1 (enExample) |
| ES (1) | ES2655437T3 (enExample) |
| IL (1) | IL222057A (enExample) |
| MX (1) | MX342000B (enExample) |
| NZ (1) | NZ603379A (enExample) |
| SG (1) | SG184165A1 (enExample) |
| TW (2) | TWI538685B (enExample) |
| WO (1) | WO2011122022A1 (enExample) |
| ZA (1) | ZA201207342B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201507719D0 (en) * | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
| GB201517538D0 (en) * | 2015-10-05 | 2015-11-18 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
| PH12022551111A1 (en) | 2015-10-05 | 2023-08-23 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0239102A3 (en) | 1986-03-28 | 1989-07-12 | Tsuji, Kimiyoshi | Process for the formation of human-human hybridoma |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5804566A (en) | 1993-08-26 | 1998-09-08 | The Regents Of The University Of California | Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides |
| US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
| US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
| EP0841945B1 (en) | 1995-08-03 | 2006-03-08 | Rijksuniversiteit te Leiden | Cell derived antigen presenting vesicles |
| US5853719A (en) | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
| JP2000516090A (ja) | 1996-07-26 | 2000-12-05 | スローン―ケッタリング インスティチュート フォー キャンサー リサーチ | 遺伝子的免疫化のための方法と試薬 |
| FR2766205B1 (fr) | 1997-07-16 | 2002-08-30 | Inst Nat Sante Rech Med | Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede |
| US7393663B2 (en) * | 1997-08-01 | 2008-07-01 | Serono Genetics Institute S.A. | Expressed sequence tags and encoded human proteins |
| US20030013649A1 (en) | 2000-01-31 | 2003-01-16 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
| EP1332153A4 (en) * | 2000-10-12 | 2006-01-11 | Exelixis Inc | HUMAN ECT2 AND METHOD OF USE THEREOF |
| US7919467B2 (en) * | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| US7227007B2 (en) * | 2000-12-28 | 2007-06-05 | Asahi Kasei Pharma Corporation | NF-κB activating gene |
| EP2336167B1 (en) | 2001-03-14 | 2019-05-29 | Dako Denmark A/S | MHC molecule constructs and their uses for diagnosis and therapy |
| US20040236091A1 (en) | 2001-03-28 | 2004-11-25 | Chicz Roman M. | Translational profiling |
| WO2002096943A1 (en) * | 2001-05-25 | 2002-12-05 | Asahi Kasei Kabushiki Kaisha | Stat6-activating genes |
| US20030092616A1 (en) | 2001-05-25 | 2003-05-15 | Akio Matsuda | STAT6 activation gene |
| WO2002099062A2 (en) | 2001-06-04 | 2002-12-12 | Curagen Corporation | Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use |
| CA2447935A1 (en) * | 2001-06-04 | 2002-12-12 | Curagen Corporation | Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use |
| CA2399569A1 (en) | 2001-09-25 | 2003-03-25 | Yusuke Nakamura | Diagnostic markers and drug targets for treatment of cancer |
| GB2392158B (en) | 2002-08-21 | 2005-02-16 | Proimmune Ltd | Chimeric MHC protein and oligomer thereof |
| WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| JP4614952B2 (ja) | 2003-08-20 | 2011-01-19 | オンコセラピー・サイエンス株式会社 | 腎細胞癌（ｒｃｃ）の潜在的な新規治療標的としての低酸素誘導タンパク質２（ｈｉｇ２） |
| WO2006031221A1 (en) | 2004-09-13 | 2006-03-23 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Compositions comprising t cell receptors and methods of use thereof |
| US7998695B2 (en) | 2005-02-10 | 2011-08-16 | Oncotherapy Science, Inc. | Method of diagnosing bladder cancer |
| EP1907582B1 (en) | 2005-07-27 | 2012-01-04 | Oncotherapy Science, Inc. | Ect2 as a therapeutic target for esophageal cancer |
| EP2305811A1 (en) | 2005-07-27 | 2011-04-06 | Oncotherapy Science, Inc. | Method of diagnosing smal cell lung cancer |
| CN101287831B (zh) | 2005-09-13 | 2013-05-15 | 国立大学法人三重大学 | T细胞受体和编码该受体的核酸 |
| CN101432022A (zh) * | 2006-02-28 | 2009-05-13 | 肿瘤疗法科学股份有限公司 | 利用抗-EphA4抗体效应物作用损伤细胞的方法 |
| AU2007311946A1 (en) | 2006-10-20 | 2008-04-24 | Forerunner Pharma Research Co., Ltd. | Anti-cancer agent comprising anti-HB-EGF antibody as active ingredient |
| JP5378795B2 (ja) | 2006-10-20 | 2013-12-25 | 中外製薬株式会社 | 抗ｈｂ−ｅｇｆ抗体を有効成分として含む医薬組成物 |
| TWI494319B (zh) * | 2007-02-21 | 2015-08-01 | Oncotherapy Science Inc | 表現腫瘤相關抗原之癌症的胜肽疫苗 |
| EP2105511A1 (en) | 2008-03-28 | 2009-09-30 | Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. | Medicament compositions and substances for treatment and identifying adenocarcinoma of the lung |
| WO2010007791A1 (en) * | 2008-07-16 | 2010-01-21 | Oncotherapy Science, Inc. | Ect2 oncogene as a therapeutic target and prognostic indicator for lung and esophageal cancer |
| TW201008574A (en) * | 2008-08-19 | 2010-03-01 | Oncotherapy Science Inc | INHBB epitope peptides and vaccines containing the same |
-
2011
- 2011-03-23 TW TW100109936A patent/TWI538685B/zh not_active IP Right Cessation
- 2011-03-23 TW TW105112382A patent/TW201627003A/zh unknown
- 2011-03-30 JP JP2012543839A patent/JP5816965B2/ja active Active
- 2011-03-30 NZ NZ603379A patent/NZ603379A/en not_active IP Right Cessation
- 2011-03-30 DK DK11762265.4T patent/DK2553096T3/en active
- 2011-03-30 BR BR112012024997-5A patent/BR112012024997B1/pt not_active IP Right Cessation
- 2011-03-30 EP EP11762265.4A patent/EP2553096B1/en active Active
- 2011-03-30 SG SG2012069696A patent/SG184165A1/en unknown
- 2011-03-30 AU AU2011233401A patent/AU2011233401B2/en not_active Ceased
- 2011-03-30 US US13/638,272 patent/US8951975B2/en active Active
- 2011-03-30 MX MX2012011385A patent/MX342000B/es active IP Right Grant
- 2011-03-30 CN CN201180027360.5A patent/CN102939379B/zh not_active Expired - Fee Related
- 2011-03-30 KR KR1020127028426A patent/KR101863557B1/ko not_active Expired - Fee Related
- 2011-03-30 CA CA2795318A patent/CA2795318C/en active Active
- 2011-03-30 WO PCT/JP2011/001909 patent/WO2011122022A1/en not_active Ceased
- 2011-03-30 ES ES11762265.4T patent/ES2655437T3/es active Active
- 2011-03-30 EA EA201291004A patent/EA027940B1/ru not_active IP Right Cessation
- 2011-04-01 AR ARP110101103A patent/AR081065A1/es unknown
-
2012
- 2012-09-23 IL IL222057A patent/IL222057A/en active IP Right Grant
- 2012-10-01 ZA ZA2012/07342A patent/ZA201207342B/en unknown
- 2012-10-03 CO CO12173572A patent/CO6571869A2/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| DK2553096T3 (en) | 2018-01-15 |
| IL222057A (en) | 2017-12-31 |
| TWI538685B (zh) | 2016-06-21 |
| SG184165A1 (en) | 2012-10-30 |
| TW201138803A (en) | 2011-11-16 |
| EP2553096A1 (en) | 2013-02-06 |
| JP2013523082A (ja) | 2013-06-17 |
| NZ603379A (en) | 2014-09-26 |
| BR112012024997B1 (pt) | 2022-03-22 |
| KR101863557B1 (ko) | 2018-06-01 |
| EP2553096B1 (en) | 2017-11-22 |
| CO6571869A2 (es) | 2012-11-30 |
| MX342000B (es) | 2016-09-09 |
| AR081065A1 (es) | 2012-06-06 |
| BR112012024997A2 (pt) | 2017-05-23 |
| US8951975B2 (en) | 2015-02-10 |
| CA2795318A1 (en) | 2011-10-06 |
| CA2795318C (en) | 2018-11-13 |
| JP5816965B2 (ja) | 2015-11-18 |
| EA027940B1 (ru) | 2017-09-29 |
| KR20130033367A (ko) | 2013-04-03 |
| EP2553096A4 (en) | 2013-11-13 |
| WO2011122022A1 (en) | 2011-10-06 |
| TW201627003A (zh) | 2016-08-01 |
| CN102939379A (zh) | 2013-02-20 |
| ZA201207342B (en) | 2013-06-26 |
| US20130095128A1 (en) | 2013-04-18 |
| AU2011233401A1 (en) | 2012-10-25 |
| AU2011233401B2 (en) | 2015-03-26 |
| CN102939379B (zh) | 2016-08-03 |
| EA201291004A1 (ru) | 2013-04-30 |
| MX2012011385A (es) | 2013-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2415958T3 (es) | Vacunas de péptidos para cánceres que expresan los polipéptidos MPHOSPH1 ó DEPDC1 | |
| TWI434853B (zh) | 腫瘤血管內皮標誌８胜肽及包含此胜肽之疫苗 | |
| ES2618896T3 (es) | Péptidos de FOXM1 y vacunas que contienen los mismos | |
| ES2566011T3 (es) | Péptido de epítopo HIG2 y URLC10 y vacunas que contienen el mismo | |
| RU2550695C2 (ru) | Олигопептиды imp-3 и содержащие их вакцины | |
| JP2012500001A (ja) | Ｉｎｈｂｂエピトープペプチドおよびそれを含むワクチン | |
| TWI441648B (zh) | Ｆｏｘｐ３胜肽疫苗 | |
| TW201000119A (en) | MYBL2 epitope peptides and vaccines containing the same | |
| ES2784862T3 (es) | Péptidos UBE2T y vacunas que los contienen | |
| TW201006486A (en) | MELK epitope peptides and vaccines containing the same | |
| ES2647900T3 (es) | Péptidos MPHOSPH1 y vacunas que incluyen los mismos | |
| US9132176B2 (en) | RAB6KIFL/KIF20A epitope peptide and vaccines containing the same | |
| ES2631952T3 (es) | Péptidos CDC45L y vacunas que incluyen los mismos | |
| ES2913148T3 (es) | Péptidos con epítopos WDRPUH y vacunas que los contienen | |
| KR20130033367A (ko) | Ｅｃｔ２펩티드 및 이를 포함한 백신 | |
| HK1157397B (en) | Rab6kifl/kif20a epitope peptide and vaccines containing the same |